Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Are commercial antibody assays substantially underestimating SARS-CoV-2 ever infection? An analysis on a population-based sample in a high exposure setting

Gheyath K. Nasrallah, View ORCID ProfileSoha R. Dargham, Farah Shurrab, Duaa W. Al-Sadeq, Hadeel Al-Jighefee, View ORCID ProfileHiam Chemaitelly, Zaina Al Kanaani, Abdullatif Al Khal, Einas Al Kuwari, Peter Coyle, Andrew Jeremijenko, Anvar Hassan Kaleeckal, Ali Nizar Latif, Riyazuddin Mohammad Shaik, Hanan F. Abdul Rahim, Hadi M. Yassine, Mohamed G. Al Kuwari, Hamda Qotba, Hamad Eid Al Romaihi, Patrick Tang, Roberto Bertollini, Mohamed Al-Thani, Asmaa A. Althani, View ORCID ProfileLaith J. Abu-Raddad
doi: https://doi.org/10.1101/2020.12.14.20248163
Gheyath K. Nasrallah
1Biomedical Research Center, Member of QU Health, Qatar University, Doha 2713, Qatar
2Department of Biomedical Science, College of Health Sciences, Member of QU Health, Qatar University, Doha 2713, Qatar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: gheyath.nasrallah@qu.edu.qa lja2002@qatar-med.cornell.edu
Soha R. Dargham
3Infectious Disease Epidemiology Group, Weill Cornell Medicine - Qatar, Cornell University, Qatar Foundation - Education City, Doha, Qatar
4World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine – Qatar, Cornell University, Qatar Foundation – Education City, Doha, Qatar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Soha R. Dargham
Farah Shurrab
1Biomedical Research Center, Member of QU Health, Qatar University, Doha 2713, Qatar
2Department of Biomedical Science, College of Health Sciences, Member of QU Health, Qatar University, Doha 2713, Qatar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Duaa W. Al-Sadeq
1Biomedical Research Center, Member of QU Health, Qatar University, Doha 2713, Qatar
2Department of Biomedical Science, College of Health Sciences, Member of QU Health, Qatar University, Doha 2713, Qatar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hadeel Al-Jighefee
1Biomedical Research Center, Member of QU Health, Qatar University, Doha 2713, Qatar
2Department of Biomedical Science, College of Health Sciences, Member of QU Health, Qatar University, Doha 2713, Qatar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hiam Chemaitelly
3Infectious Disease Epidemiology Group, Weill Cornell Medicine - Qatar, Cornell University, Qatar Foundation - Education City, Doha, Qatar
4World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine – Qatar, Cornell University, Qatar Foundation – Education City, Doha, Qatar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Hiam Chemaitelly
Zaina Al Kanaani
5Hamad Medical Corporation, Doha, Qatar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Abdullatif Al Khal
5Hamad Medical Corporation, Doha, Qatar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Einas Al Kuwari
5Hamad Medical Corporation, Doha, Qatar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Coyle
5Hamad Medical Corporation, Doha, Qatar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew Jeremijenko
5Hamad Medical Corporation, Doha, Qatar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anvar Hassan Kaleeckal
5Hamad Medical Corporation, Doha, Qatar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ali Nizar Latif
5Hamad Medical Corporation, Doha, Qatar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Riyazuddin Mohammad Shaik
5Hamad Medical Corporation, Doha, Qatar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hanan F. Abdul Rahim
6College of Health Sciences, QU Health, Qatar University, Doha, Qatar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hadi M. Yassine
1Biomedical Research Center, Member of QU Health, Qatar University, Doha 2713, Qatar
2Department of Biomedical Science, College of Health Sciences, Member of QU Health, Qatar University, Doha 2713, Qatar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mohamed G. Al Kuwari
7Primary Health Care Corporation, Doha, Qatar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hamda Qotba
7Primary Health Care Corporation, Doha, Qatar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hamad Eid Al Romaihi
8Ministry of Public Health, Doha, Qatar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrick Tang
9Department of Pathology, Sidra Medicine, Doha, Qatar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roberto Bertollini
8Ministry of Public Health, Doha, Qatar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mohamed Al-Thani
8Ministry of Public Health, Doha, Qatar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Asmaa A. Althani
1Biomedical Research Center, Member of QU Health, Qatar University, Doha 2713, Qatar
2Department of Biomedical Science, College of Health Sciences, Member of QU Health, Qatar University, Doha 2713, Qatar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laith J. Abu-Raddad
3Infectious Disease Epidemiology Group, Weill Cornell Medicine - Qatar, Cornell University, Qatar Foundation - Education City, Doha, Qatar
4World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine – Qatar, Cornell University, Qatar Foundation – Education City, Doha, Qatar
10Department of Population Health Sciences, Weill Cornell Medicine, Cornell University, New York, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Laith J. Abu-Raddad
  • For correspondence: gheyath.nasrallah@qu.edu.qa lja2002@qatar-med.cornell.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Performance of three automated commercial serological IgG-based assays was investigated for assessing SARS-CoV-2 ever (past or current) infection in a population-based sample in a high exposure setting.

Methods PCR and serological testing was performed on 394 individuals.

Results SARS-CoV-2-IgG seroprevalence was 42.9% (95% CI 38.1%-47.8%), 40.6% (95% CI 35.9%-45.5%), and 42.4% (95% CI 37.6%-47.3%) using the CL-900i, VidasIII, and Elecsys assays, respectively. Between the three assays, overall, positive, and negative percent agreements ranged between 93.2%-95.7%, 89.3%-92.8%, and 93.8%-97.8%, respectively; Cohen kappa statistic ranged from 0.86-0.91; and 35 specimens (8.9%) showed discordant results. Among all individuals, 12.5% (95% CI 9.6%-16.1%) had current infection, as assessed by PCR. Of these, only 34.7% (95% CI 22.9%-48.7%) were seropositive by at least one assay. A total of 216 individuals (54.8%; 95% CI 49.9%-59.7%) had evidence of ever infection using antibody testing and/or PCR during or prior to this study. Of these, only 78.2%, 74.1%, and 77.3% were seropositive in the CL-900i, VidasIII, and Elecsys assays, respectively.

Conclusions All three assays had comparable performance and excellent agreement, but missed at least 20% of individuals with past or current infection. Commercial antibody assays can substantially underestimate ever infection, more so when infection rates are high.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

The authors are grateful for support provided by Qatar University, Ministry of Public Health, Hamad Medical Corporation, and the Biomedical Research Program and the Biostatistics, Epidemiology, and Biomathematics Research Core, both at Weill Cornell Medicine-Qatar. Part of this work was made possible by grant No. RRC-2-032 from the Qatar National Research Fund (a member of Qatar Foundation) given to GKN. Finally, we would like to thank the BioMerieux Middle East Regional Office and their distributor in Qatar for providing us with the VidasIII reagent as in-kind support for this project. The statements made herein are solely the responsibility of the authors.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The research work was approved by the ethics review boards at HMC, QU, and Weill Cornell Medicine-Qatar

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All relevant data are available within the manuscript.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted December 14, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Are commercial antibody assays substantially underestimating SARS-CoV-2 ever infection? An analysis on a population-based sample in a high exposure setting
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Are commercial antibody assays substantially underestimating SARS-CoV-2 ever infection? An analysis on a population-based sample in a high exposure setting
Gheyath K. Nasrallah, Soha R. Dargham, Farah Shurrab, Duaa W. Al-Sadeq, Hadeel Al-Jighefee, Hiam Chemaitelly, Zaina Al Kanaani, Abdullatif Al Khal, Einas Al Kuwari, Peter Coyle, Andrew Jeremijenko, Anvar Hassan Kaleeckal, Ali Nizar Latif, Riyazuddin Mohammad Shaik, Hanan F. Abdul Rahim, Hadi M. Yassine, Mohamed G. Al Kuwari, Hamda Qotba, Hamad Eid Al Romaihi, Patrick Tang, Roberto Bertollini, Mohamed Al-Thani, Asmaa A. Althani, Laith J. Abu-Raddad
medRxiv 2020.12.14.20248163; doi: https://doi.org/10.1101/2020.12.14.20248163
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Are commercial antibody assays substantially underestimating SARS-CoV-2 ever infection? An analysis on a population-based sample in a high exposure setting
Gheyath K. Nasrallah, Soha R. Dargham, Farah Shurrab, Duaa W. Al-Sadeq, Hadeel Al-Jighefee, Hiam Chemaitelly, Zaina Al Kanaani, Abdullatif Al Khal, Einas Al Kuwari, Peter Coyle, Andrew Jeremijenko, Anvar Hassan Kaleeckal, Ali Nizar Latif, Riyazuddin Mohammad Shaik, Hanan F. Abdul Rahim, Hadi M. Yassine, Mohamed G. Al Kuwari, Hamda Qotba, Hamad Eid Al Romaihi, Patrick Tang, Roberto Bertollini, Mohamed Al-Thani, Asmaa A. Althani, Laith J. Abu-Raddad
medRxiv 2020.12.14.20248163; doi: https://doi.org/10.1101/2020.12.14.20248163

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (70)
  • Allergy and Immunology (168)
  • Anesthesia (49)
  • Cardiovascular Medicine (448)
  • Dentistry and Oral Medicine (80)
  • Dermatology (55)
  • Emergency Medicine (157)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (190)
  • Epidemiology (5216)
  • Forensic Medicine (3)
  • Gastroenterology (194)
  • Genetic and Genomic Medicine (750)
  • Geriatric Medicine (77)
  • Health Economics (212)
  • Health Informatics (694)
  • Health Policy (352)
  • Health Systems and Quality Improvement (223)
  • Hematology (98)
  • HIV/AIDS (162)
  • Infectious Diseases (except HIV/AIDS) (5816)
  • Intensive Care and Critical Care Medicine (356)
  • Medical Education (102)
  • Medical Ethics (25)
  • Nephrology (80)
  • Neurology (758)
  • Nursing (43)
  • Nutrition (129)
  • Obstetrics and Gynecology (141)
  • Occupational and Environmental Health (231)
  • Oncology (475)
  • Ophthalmology (149)
  • Orthopedics (38)
  • Otolaryngology (93)
  • Pain Medicine (39)
  • Palliative Medicine (19)
  • Pathology (139)
  • Pediatrics (223)
  • Pharmacology and Therapeutics (136)
  • Primary Care Research (96)
  • Psychiatry and Clinical Psychology (854)
  • Public and Global Health (1993)
  • Radiology and Imaging (344)
  • Rehabilitation Medicine and Physical Therapy (157)
  • Respiratory Medicine (283)
  • Rheumatology (93)
  • Sexual and Reproductive Health (72)
  • Sports Medicine (75)
  • Surgery (108)
  • Toxicology (25)
  • Transplantation (29)
  • Urology (39)